

---

# RESAR Update

SEMIANNUAL MEETING SSO MARCH 20TH 2024





# New RESAR setting

47 RECRUITING SITES

Website

[www.resarplatform.com](http://www.resarplatform.com)

8 Centers

Ok with contracts  
Need to contact BBS for upload of  
historical data  
(already contacted by  
[jasmine.tadiotto@bbsitalia.com](mailto:jasmine.tadiotto@bbsitalia.com))

RESAR centralized on  
RESAR PLATFORM

17 centers online

30 centers need to  
complete process

Platform Support

[Daniela.Salvatore@resarplatform.com](mailto:Daniela.Salvatore@resarplatform.com)


22 centers

Need to complete contracts  
(already contacted by  
[Silvia.Taverna@istitutotumori.mi.it](mailto:Silvia.Taverna@istitutotumori.mi.it))

# New RESAR setting

47 RECRUITING SITES

- **1215 patients/17 centers already online**
  - Last “declared” update on enrollment in Feb 2023: 3332 patients/46 centers
- **Users in the Platform:**
  - Administrator (Daniela Salvatore)
  - Researcher: privileges only for his/her own site
  - Study Principal Investigators: (anonymized) privileges for all patients enrolled in a study project
- **Data entry**
  - Manual, online: largely preferred by participating centers (only option for new centers)
  - Semiautomatic upload/update: only available by official RESAR files (FileMaker, Excel) → CANNOT MODIFY DATA ONLINE!
- **Patient IDs**
  - Enter data with **LOCAL Patient ID**, algorithm will return pseudonymized **RESAR ID**
  - Researchers will be able online to:
    - Revert **Local Patient ID** ↔ **RESAR ID**
    - Download full list of correspondences of RESAR IDs and Local IDs for his/her hospital
- **RESAR Studies**
  - The Platform is compliant to build new RESAR Studies on the online database
  - Can be compliant to specific new CRFs or new datafield for specific study
  - Compliant to offer online randomization of patients enrolled in RESAR prospective studies (e.g. SARVeillance)



# Recruiting Centers – Pending steps for Go-LIVE



Centers with contracts already signed,  
need to complete upload of historical data on  
RESAR Platform

| Center                           | City      |
|----------------------------------|-----------|
| Winship Cancer Institute         | Atlanta   |
| Princess Alexandra Hospital      | Brisbane  |
| Leiden University Medical Center | Leiden    |
| Royal Marsden Hospital           | London    |
| Mannheim Univ. Medical Center    | Mannheim  |
| UC San Diego                     | San Diego |
| National Cancer Center Hospital  | Tokyo     |
| Maria Sklodowska-Curie           | Warsaw    |

Check previous contact from  
[Jasmine.Tadiotto@bbsitalia.com](mailto:Jasmine.Tadiotto@bbsitalia.com)



## Recruiting Centers – Pending steps for Go-LIVE

Centers actively recruiting,  
But need to finalize contract before being  
allowed to centralized data on the RESAR  
Platform

Check recent contact from  
[Silvia.Taverna@istitutotumori.mi.it](mailto:Silvia.Taverna@istitutotumori.mi.it)

**BEWARE:** for future RESAR studies (after 5-  
studies season), only center with centralized  
online data will be allowed to participate!

| Center                                                 | City         | Center                                                        | City      |
|--------------------------------------------------------|--------------|---------------------------------------------------------------|-----------|
| Hospital Sant Pau                                      | Barcelona    | N.N. Blokhin Medical Research Center of Oncology              | Moskow    |
| Mary Bird Perkins Cancer Center                        | Baton Rouge  | Tata Memorial Hospital                                        | Mumbai    |
| Peking University International Hospital               | Beijing      | Hospital Clinico Universitario "Virgen de la Arrixaca"        | Murcia    |
| Institut Bergonié                                      | Bordeaux     | Sultan Qaboos Comprehensive Cancer Care and Research Al Khoud | Muscat    |
| Roswell Park Comprehensive Cancer Center               | Buffalo      | Veneto Institute of Oncology                                  | Padova    |
| Candiolo Cancer Institute                              | Candiolo     | A.C. Camargo Cancer Center                                    | Sao Paulo |
| The University of Kansas Health System                 | Kansans City | Samsung Medical Center                                        | Seoul     |
| National Cancer Institute                              | Kyiv         | Moffitt Cancer Center                                         | Tampa     |
| Liverpool University Hospitals NHS Foundation trust    | Liverpool    | Tel-Aviv Sourasky Medical Center                              | Tel-Aviv  |
| Maisonneuve-Rosemont Hospital / University of Montreal | Montreal     | Christian Medical College                                     | Vellore   |
| McGill University                                      | Montreal     | Ospedale Borgo Roma                                           | Verona    |



# New RESAR setting

47 RECRUITING SITES

| Hospital                                                                             | Total number of patients | Complete data entry | Follow up older than 1yr |
|--------------------------------------------------------------------------------------|--------------------------|---------------------|--------------------------|
| 1 Fondazione IRCCS Istituto Nazionale dei Tumori                                     | 503<br>26.4%             | 350<br>69.6%        | 227                      |
| 5 Institut Curie                                                                     | 263<br>13.8%             | 96<br>36.5%         | 44                       |
| 3 Queen Elizabeth Hospital Birmingham                                                | 156<br>8.2%              | 71<br>45.5%         | 118                      |
| 21 Peter MacCallum Cancer Center                                                     | 142<br>7.4%              | 19<br>13.4%         | 46                       |
| 24 Mount Sinai Hospital and Princess Margaret Hospital                               | 127<br>6.7%              | 0<br>0%             | 84                       |
| 11 Humanitas Cancer Center                                                           | 127<br>6.7%              | 65<br>51.2%         | 25                       |
| 16 Ludwig Maximilian University                                                      | 111<br>5.8%              | 2<br>1.8%           | 80                       |
| 26 Netherlands Cancer Institute                                                      | 106<br>5.6%              | 0<br>0%             | 37                       |
| 4 Brigham and Women's Hospital, Dana-Farber Cancer Institute, Harvard Medical School | 87<br>4.6%               | 0<br>0%             | 33                       |
| 12 Istituto Europeo di Oncologia                                                     | 55<br>2.9%               | 0<br>0%             | 40                       |
| 27 The Ottawa Hospital                                                               | 50<br>2.6%               | 30<br>60%           | 42                       |
| 28 Ohio State University                                                             | 47<br>2.5%               | 12<br>25.5%         | 36                       |
| 14 Johns Hopkins' University                                                         | 46<br>2.4%               | 0<br>0%             | 19                       |
| 65 Institute of Oncology Ljubljana                                                   | 46<br>2.4%               | 41<br>89.1%         | 2                        |
| 46 Campus Biomedico                                                                  | 23<br>1.2%               | 4<br>17.4%          | 9                        |
| 133 Royal Prince Alfred Hospital / Chris O'Brien Lifehouse                           | 17<br>0.9%               | 2<br>11.8%          | 16                       |
| 13 Mayo Clinic Florida                                                               | 1<br>0.1%                | 0<br>0%             | 0                        |
| Total                                                                                | 1907                     | 692<br>36.3%        | 858                      |

# CONTRACTS

# TARPSWG

PLEASE CONTACT [marco.fiore@istitutotumori.mi.it](mailto:marco.fiore@istitutotumori.mi.it) TO BE PREPARED

# 47 RESAR Centers



|                                              |       |       |
|----------------------------------------------|-------|-------|
|                                              |       |       |
| Recruiting Centers                           | 47    |       |
| <b>Contracts</b>                             |       |       |
| Framework Agreement signed                   | 24/47 | 51.1% |
| Framework Agreement pending (for site delay) | 23/47 | 48.9% |
| <b>5-Studies</b>                             |       |       |
| DUF 5-Studies signed                         | 21/28 | 75%   |
| Declined participation                       | 7/28  | 25%   |

# IRB APPROVAL – LOCAL DOCUMENTS

# TARPSWG

PLEASE CONTACT [marco.fiore@istitutotumori.mi.it](mailto:marco.fiore@istitutotumori.mi.it) TO BE PREPARED

# IRB Approval

PLEASE CONTACT: [DANIELA.SALVATORE@RESARPLATFORM.COM](mailto:DANIELA.SALVATORE@RESARPLATFORM.COM)



- RESAR is a prospective, observational study
- Patients can be prospectively enrolled, since date of local IRB approval
- Patients are required to be consented (data collection, international data sharing, future analysis on the database)

| Recruiting Center                                      | City      | IRB Information     |
|--------------------------------------------------------|-----------|---------------------|
| Johns Hopkins University                               | Baltimore | Expired             |
| Hospital Sant Pau                                      | Barcelona | Missing information |
| Peking University International Hospital               | Beijing   | Expired             |
| Institut Bergonié                                      | Bordeaux  | Expired             |
| Roswell Park Comprehensive Cancer Center               | Buffalo   | Expired             |
| Candiolo Cancer Institute                              | Candiolo  | Expired             |
| Liverpool University Hospitals NHS Foundation trust    | Liverpool | Expired             |
| Mannheim University Medical Center                     | Mannheim  | Expired             |
| Maisonnette-Rosemont Hospital / University of Montreal | Montreal  | Missing information |
| N.N. Blokhin Medical Research Center of Oncology       | Moscow    | Expired             |
| Hospital Clinico Universitario "Virgen de la Arrixaca" | Murcia    | Missing information |
| The Ottawa Hospital                                    | Ottawa    | Expired             |
| Institut Curie                                         | Paris     | Expired             |
| UC San Diego                                           | San Diego | Expired             |
| Samsung Medical Center                                 | Seoul     | Expired             |
| Moffitt Cancer Center                                  | Tampa     | Expired             |
| Mount Sinai / Princess Margaret                        | Toronto   | Expired             |
| Christian Medical College                              | Vellore   | Expired             |

# IRB Approval

PLEASE CONTACT: [DANIELA.SALVATORE@RESARPLATFORM.COM](mailto:DANIELA.SALVATORE@RESARPLATFORM.COM)



- RESAR is a prospective, observational study
- Patients can be prospectively enrolled, since date of local IRB approval
- Patients are required to be consented (data collection, international data sharing, future analysis on the database)

| Centers to be activated                          | City         | IRB Information |
|--------------------------------------------------|--------------|-----------------|
| Centro di Riferimento Oncologico                 | Aviano       | Yes             |
| Instituto Nacional de Cancerología               | Bogotá       | <b>Expired</b>  |
| Instituto de Oncologia Angel Roffo               | Buenos Aires | Yes             |
| Ospedale Garibaldi                               | Catania      | Yes             |
| Tallaght Univesity Hospital                      | Dublin       | <b>No</b>       |
| Patel Hospital                                   | Karachi      | Yes             |
| St James's University Hospital                   | Leeds        | Yes             |
| INCMN Salvador Zubirán                           | Mexico City  | Yes             |
| Instituto National de Cancerologia               | Mexico City  | Yes             |
| Sylvester Comprehensive Cancer Center            | Miami        | Yes             |
| Fox Chase Cancer Center                          | Philadelphia | Yes             |
| Portuguese Institute for Oncology Porto IPO      | Porto        | <b>No</b>       |
| Saitama Medical Center, Jichi Medical University | Saitama      | <b>Expired</b>  |
| Westmead Hospital                                | Sydney       | Yes             |
| Sheba Medical Centre                             | Tel-Aviv     | Yes             |
| Aretaieio University Hospital                    | Athens       | Yes             |
| City of Hope National Medical Center             | Duarte       | Yes             |
| Vancouver General Hospital and BC Cancer/UBC     | Vancouver    | Yes             |

# IRB Approval



- RESAR is a prospective, observational study
- Patients can be prospectively enrolled, since date of local IRB approval
- Patients are required to be consented (data collection, international data sharing, future analysis on the database)

- To communicate updates on your local documents approval AND/OR assistance, please contact:

**[daniela.salvatore@resarplatform.com](mailto:daniela.salvatore@resarplatform.com)**

## 5 - Studies

TARPSWG

PLEASE CONTACT [marco.fiore@istitutotumori.mi.it](mailto:marco.fiore@istitutotumori.mi.it) TO BE PREPARED






# Data Collection CLOSED

| Study                   | ID    | PIs                                      | Study time-frame    | Participating Centers | Number of Patients | Statistician              |
|-------------------------|-------|------------------------------------------|---------------------|-----------------------|--------------------|---------------------------|
| BISARC                  | R1905 | S. Dumitra<br>A. Gronchi                 | Jan 2017 – Jan 2020 | 17 (21)               | 934                | R. Miceli (Milan)         |
| Patterns of Care        | R2005 | H. Snow<br>D. Gyorki                     | Jan 2017 – Jul 2022 | 19 (29)               | 1926               | Sophia Xie<br>(Melbourne) |
| Response to Neoadjuvant | R2007 | W. Van Houdt<br>A. Gronchi<br>S. Reijers | Jan 2017 – Oct 2020 | 14 (19)               | 175                | TBD                       |
| ResAntiPath             | R2006 | M. Fiore<br>A. Gronchi<br>D. Strauss     | Jan 2017 – Jan 2020 | 17 (22)               | 976                | R. Miceli (Milan)         |
| Benchmarks              | R1906 | A. Gronchi<br>F. Tirotta<br>M. Fiore     | Jan 2017 – Dec 2021 | 16 (24)               | 1569               | TBD                       |

Clean Dataset will be sent to study PIs as soon as response to queries will be received.

Still missing: Ottawa, Tel-Aviv

# 5–studies composition



# FOR NEW CENTERS: HOW TO JOIN RESAR

OPEN TO ANY TARPSWG CENTER



## DECLARATION OF INTEREST

Please contact:

[marco.fiore@resarplatform.com](mailto:marco.fiore@resarplatform.com)

[tarpswg@gmail.com](mailto:tarpswg@gmail.com)

## FOR DATA TRANSFER AGREEMENT

Contact

[marco.fiore@resarplatform.com](mailto:marco.fiore@resarplatform.com)

[daniela.salvatore@resarplatform.com](mailto:daniela.salvatore@resarplatform.com)

DOCUMENTS: STUDY  
PROTOCOL, DATASET

LOCAL IRB  
APPROVAL

JOIN FRAMEWORK  
AGREEMENT

CENTER  
ACTIVATION

FIND MATERIALS AND DOWNLOAD HERE:

[tarpswg.org/resar-study-documentation](https://tarpswg.org/resar-study-documentation)

LOGINS FOR EXTRA  
PLATFORM FOR ONLINE  
DATA ENTRY WILL BE  
RELEASED